Latest news with #DouglasMiehm
Business Insider
a day ago
- Business
- Business Insider
RBC Capital Remains a Buy on DRI Healthcare (DHT.UN)
RBC Capital analyst Douglas Miehm maintained a Buy rating on DRI Healthcare ( – Research Report) on June 12 and set a price target of C$19.00. The company's shares closed yesterday at C$13.33. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Miehm covers the Healthcare sector, focusing on stocks such as WELL Health Technologies Corp, Knight Therapeutics, and Bausch + Lomb Corporation. According to TipRanks, Miehm has an average return of -1.7% and a 41.61% success rate on recommended stocks. Currently, the analyst consensus on DRI Healthcare is a Strong Buy with an average price target of C$17.00. The company has a one-year high of C$16.26 and a one-year low of C$10.39. Currently, DRI Healthcare has an average volume of 42.45K. Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of in relation to earlier this year.
Business Insider
15-05-2025
- Business
- Business Insider
RBC Capital Sticks to Their Buy Rating for DRI Healthcare (DHT.UN)
RBC Capital analyst Douglas Miehm maintained a Buy rating on DRI Healthcare ( – Research Report) yesterday and set a price target of C$18.00. The company's shares closed yesterday at C$12.48. Confident Investing Starts Here: Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter Miehm covers the Healthcare sector, focusing on stocks such as Bausch + Lomb Corporation, Ligand Pharma, and Bausch Health Companies. According to TipRanks, Miehm has an average return of -2.3% and a 39.85% success rate on recommended stocks. Currently, the analyst consensus on DRI Healthcare is a Strong Buy with an average price target of C$16.67, a 33.57% upside from current levels. In a report released yesterday, Stifel Nicolaus also maintained a Buy rating on the stock with a C$17.00 price target.
